Mirabegron
- Product NDC
- 73190-116
- Requested package NDC
- 73190-116-30
- 11-digit product format
- 731900116
- Labeler code
- 73190
- Product ID
- 73190-116_5f102149-ad28-4956-e063-6294a90ac6ad
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Mirabegron
- Dosage form
- TABLET, FILM COATED, EXTENDED RELEASE
- Route
- ORAL
- Labeler
- AvKARE
- Application
- ANDA218543
- Marketing category
- ANDA
- Marketing start
- 2026-10-30
- Substance
- MIRABEGRON
- Active strength
- 50 mg/1
- Pharmacologic classes
- Adrenergic beta3-Agonists [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], beta3-Adrenergic Agonist [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A218543-001 | MIRABEGRON | MIRABEGRON | 25MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | |
| A218543-002 | MIRABEGRON | MIRABEGRON | 50MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A218543-001 | AB |
| A218543-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A218543-001 | MIRABEGRON | 25MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A218543-002 | MIRABEGRON | 50MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A218543-001 | MIRABEGRON | 25MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A218543-002 | MIRABEGRON | 50MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A218543-001 | MIRABEGRON | 25MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A218543-002 | MIRABEGRON | 50MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A218543-001 | MIRABEGRON | 25MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A218543-002 | MIRABEGRON | 50MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A218543-001 | MIRABEGRON | 25MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A218543-002 | MIRABEGRON | 50MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A218543-001 | MIRABEGRON | 25MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A218543-002 | MIRABEGRON | 50MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | 31067a03dcf5… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218543-001 | MIRABEGRON | 25MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218543-002 | MIRABEGRON | 50MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2025-11-04 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A218543-001 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A218543-002 | AB | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A218543-001 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A218543-002 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A218543-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A218543-002 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A218543-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A218543-002 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A218543-001 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A218543-002 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A218543-001 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A218543-002 | AB | 1 | 31067a03dcf5… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218543-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218543-002 | AB | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Mirabegron
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| MIRABEGRON | 50 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| MVR3JL3B2V | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 5f102149-ad27-4956-e063-6294a90ac6ad | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Mirabegron | MIRABEGRON | AvKARE | 5f102149-ad27-4956-e063-6294a90ac6ad | 2026-10-30 | Warnings, Adverse reactions | 218543 ANDA218543 73190-116-30 73190-116 73190011630 |
| Mirabegron | MIRABEGRON | Amneal Pharmaceuticals NY LLC | e597023d-6dcc-4d9e-8ce0-2d28a5d862f3 | 2026-03-26 | Warnings, Adverse reactions | 218543 ANDA218543 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 73190-116-30 | 73190011630 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (73190-116-30) | 2026-10-30 | No | No | Current |